AbCellera, Novartis partner on antibody discovery

AbCellera Biologics Inc. (Vancouver, B.C.) will use its single cell screening platform to discover antibodies against 10 undisclosed targets chosen by Novartis AG (NYSE:NVS; SIX:NOVN). AbCellera CEO Carl Hansen told BioCentury the company expects to complete the first two programs within six months, but declined to disclose indications.

AbCellera will receive an undisclosed upfront payment and be eligible for milestones and royalties...